TSHA - חובות לטווח קצר של החברה Taysha

Taysha Gene Therapies (TSHA) develops treatments for rare brain pathologies, where extensive testing and technological complexity ensure long-term patent protection. Market fluctuations in the share price demonstrate the 0.00 metric, while the business remains independent of economic conditions, relying solely on regulatory verdicts. High scientific potential in Rett syndrome therapy creates a robust barrier to entry for new players.

Liquidity analysis is critical for assessing the stability of the biotechnology sector. This metric measures the total volume of liabilities maturing within one year. Short-term loan debt dynamics help identify the risk of cash flow gaps when financing research and development. For Taysha Gene Therapies (TSHA), this indicator reflects the cost of maintaining target gene delivery platforms. The stability of this line confirms the company's ability to leverage tax preferences associated with orphan drug status.